Truist analyst Gregory Renza raised the firm’s price target on Ideaya Biosciences (IDYA) to $60 from $59 and keeps a Buy rating on the shares. Ideaya, a top pick for 2026, is approaching a key near-term catalyst with daro’s topline progression free survival readout in first line uveal melanoma in 1Q26, the analyst tells investors in a research note. Strong Phase II data and supportive key opinion leader feedback make the setup attractive, with an 85% probability of success in Good/Best Case scenarios and potential 15%-25% upside, Truist says.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences Advances with IDE892 Study Targeting MTAP-Deleted Tumors
- IDEAYA Biosciences Faces Collaboration Termination by GSK
- Citi places Ideaya on ‘upside 90-day catalyst watch’ into data
- Promising Outlook for IDEAYA Biosciences: Buy Rating Backed by Positive Trial Expectations
- Ideaya Biosciences completes enrollment in OptimUM-02 trial